Genomma Lab Internacional S.A.B. de C.V (LABB) fair value: what the stock is really worth
As of Oct 14, 2026: fair value of Genomma Lab Internacional S.A.B. de C.V MXN 33.27, price MXN 13.78, upside +141.4%, quality 59 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
60‑month range 10.70 MXN – 27.09 MXN · fair‑value band 22.56 MXN – 45.39 MXN · the 13.78 MXN price screens below the 33.27 MXN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 2, 2026.
Follow Genomma Lab Internacional S.A.B. de C.V in your weekly email
Every Wednesday you see whether Genomma Lab Internacional S.A.B. de C.V is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Mexico and internationally.
Show moreShow less
It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hair loss, ointment for muscle pain, anti-fungal treatments for the relief of colitis, products to counter stress levels, anti-wrinkles, antacids, anti-ulcers, anti-flu, protection and improvement products, treatments against hemorrhoids, against varicose veins, osteoarthritis, ophthalmic medications, infant nutrition, and others.
Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico.
Stock analysis
Genomma Lab Internacional S.A.B. de C.V (LABB) currently trades at 13.78 MXN, while our model-based Fair Value estimate is 33.27 MXN, implying the stock looks roughly 58.6% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 38.79 MXN per share, and 22 of the 26 models we run sit above the 13.78 MXN price.
Bear case: the Asset-Based group reads lowest at 7.61 MXN, and 4 of the 26 models stay below the price. Data coverage for this calculation is low.
Scenario range: 22.56 MXN (bear) to 45.39 MXN (bull), the price of 13.78 MXN sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Genomma Lab Internacional S.A.B. de C.V reported revenue of 17.5B MXN in FY2025 versus 15.5B MXN in FY2021, a compound +3.2%/yr. Reported net income was 1.6B MXN in FY2025, compounding +5.4%/yr from FY2021.
Key figures
Market cap 13.5B MXN (≈ $729M) · P/E ratio 8.3 · P/S ratio 0.76 · EPS (TTM) 1.66 MXN · Dividend yield 5.8% · Net margin 9.2% · Return on equity 14.2% · Return on assets (EBIT) 15.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 57 out of 100 (low confidence).
What moves the price
The share trades about 28% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −22% fair-value upside, at 141%, LABB screens cheaper than that median.
Fair Value models
Bear22.56 MXNFair Value 33.27 MXNBull45.39 MXN
Price 13.78 MXN · Upside +141.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.6786 MXN per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF24.74 MXN38.55 MXN57.92 MXN80
Growth DCF24.70 MXN37.54 MXN54.79 MXN78
Owner Earnings24.12 MXN37.61 MXN56.53 MXN76
All 26 models by family
DCF Models
FCF DCF24.74 MXN38.55 MXN57.92 MXN80
Owner Earnings24.12 MXN37.61 MXN56.53 MXN76
5Y Revenue Exit29.01 MXN49.59 MXN76.47 MXN71
5Y EBITDA Exit32.80 MXN56.93 MXN85.82 MXN74
5Y P/E Exit23.43 MXN38.79 MXN55.28 MXN70
10Y Revenue Exit26.00 MXN43.48 MXN68.13 MXN65
10Y EBITDA Exit29.17 MXN48.23 MXN74.86 MXN67
10Y P/E Exit23.63 MXN36.50 MXN52.87 MXN63
Earnings-Based
Graham-Dodd11.22 MXN41.13 MXN55.52 MXN64
Lynch FV9.81 MXN14.01 MXN18.22 MXN61
PEG = 1.09.81 MXN14.01 MXN18.22 MXN57
EPV21.90 MXN25.12 MXN27.81 MXN74
Dividend Discount
Gordon GGM6.21 MXN11.19 MXN15.41 MXN68
DDM Multi-Stage6.21 MXN10.23 MXN11.96 MXN67
Multiples
P/E Multiple27.24 MXN36.32 MXN45.39 MXN63
P/S Multiple21.05 MXN28.06 MXN35.08 MXN58
P/B Multiple21.05 MXN28.06 MXN35.08 MXN55
EV/EBIT47.25 MXN63.58 MXN79.90 MXN66
EV/EBITDA42.68 MXN57.48 MXN72.28 MXN67
EV/Revenue33.23 MXN48.21 MXN63.19 MXN53
Asset-Based
NCAV (Graham)5.68 MXN7.61 MXN11.36 MXN54
Growth DCF
Growth DCF24.70 MXN37.54 MXN54.79 MXN78
Rev-Margin DCF29.01 MXN49.34 MXN73.74 MXN72
Economic Profit
Residual Income10.60 MXN12.60 MXN16.92 MXN76
ROIC Compounder23.73 MXN29.75 MXN36.65 MXN72
Growth Earnings
Growth-Adj P/E18.96 MXN27.08 MXN35.21 MXN67
P/S and P/B multiple show the same value here: both are capped by the same earnings anchor (earnings per share times 17), because margin and return on equity do not support the sector multiple.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.67/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−5.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.8%
Start year 2020 (pandemic). Over 10 years: +4.7% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in MXN ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in MXN: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+10.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+4.8%
Dividend (yield on the price)5.8%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.21% → 21%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−0.8%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.5%
Yearly sales growth analysts expect, extended to five years.
After inflation (Mexico: IMF forecast 3.3% a year to 2030, 4.8% from 2016 to 2025) that is about −3.9% a year for the price and +0.3% for the forecasts.
Compare Genomma Lab Internacional S.A.B. de C.V with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 590 stocks
Beats the industry median on 13/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score59 · Above median
Fair Value upside+141.4% · Top 25%
Profitability
Return on equity (12 months)14.2% · Top 25%
Return on assets6.8% · Above median
Net margin (12 months)9.6% · Above median
Operating margin (12 months)20.0% · Top 25%
Growth and dividend
Revenue growth−6.0% · Below median
Dividend yield (12 months)5.8% · Top 25%
Balance sheet
Debt / equity0.43× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Genomma Lab Internacional S.A.B. de C.V Fair Value". https://www.fairvalue-calculator.com/stock/LABB
Frequently asked questions
Is Genomma Lab Internacional S.A.B. de C.V (LABB) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of 33.27 MXN versus a price of 13.78 MXN, about +141% upside (undervalued).
What is the fair value of LABB?
Our model-based fair value for Genomma Lab Internacional S.A.B. de C.V is 33.27 MXN (as of Oct 2, 2026), built from audited fundamentals. The current price: 13.78 MXN.
What is the quality score of LABB?
Genomma Lab Internacional S.A.B. de C.V has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Genomma Lab Internacional S.A.B. de C.V (LABB)?
Our model-based price target is the fair value of 33.27 MXN (as of Oct 2, 2026) from 26 valuation models. Cautious scenario 22.56 MXN, optimistic scenario 45.39 MXN. It is a calculation from audited fundamentals, not an analyst target.
What is the Genomma Lab Internacional S.A.B. de C.V stock forecast for 2026?
Our models put fair value at 33.27 MXN, about +141% upside versus a price of 13.78 MXN (undervalued). Cautious scenario 22.56 MXN, optimistic scenario 45.39 MXN. The calculation is refreshed regularly with new filings.
What is the revenue of Genomma Lab Internacional S.A.B. de C.V (LABB)?
Genomma Lab Internacional S.A.B. de C.V reported trailing-twelve-month revenue of about 17.0B MXN (latest available figure, as of Oct 2, 2026).
Does Genomma Lab Internacional S.A.B. de C.V pay a dividend?
Genomma Lab Internacional S.A.B. de C.V currently shows a dividend yield of about 5.81% relative to its recent price (as of Oct 2, 2026).
What growth is priced into Genomma Lab Internacional S.A.B. de C.V (LABB)?
For today's price to be fair in a discounted-cash-flow model, Genomma Lab Internacional S.A.B. de C.V would have to grow free cash flow by -0.8 % per year for five years (discount rate 12.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.8 % per year. As of Oct 2, 2026.
What discount rate (WACC) does the fair value of LABB use?
Our models discount Genomma Lab Internacional S.A.B. de C.V at 12.0 %: a base by market capitalisation (small), damped by beta 0.12, country premium for Mexico. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Genomma Lab Internacional S.A.B. de C.V that is -0.8 % per year a year over ten years, using the same discount rate (12.0 %) and the same formula as our fair value.
How much growth has Genomma Lab Internacional S.A.B. de C.V (LABB) delivered so far?
Over the past 5 years revenue at Genomma Lab Internacional S.A.B. de C.V grew +4.8 % a year. The price currently implies -0.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Genomma Lab Internacional S.A.B. de C.V (LABB) growing?
The median revenue growth in the sector is +5.4 % a year. That is the yardstick for the growth priced into Genomma Lab Internacional S.A.B. de C.V (-0.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Genomma Lab Internacional S.A.B. de C.V (LABB)?
The free-cash-flow yield on the price is 15.05 %: that much free cash flow Genomma Lab Internacional S.A.B. de C.V produces per unit of market value. When it exceeds the discount rate of our models (12.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Genomma Lab Internacional S.A.B. de C.V (LABB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Genomma Lab Internacional S.A.B. de C.V it is 33.27 MXN per share (as of Oct 2, 2026), against a price of 13.78 MXN. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Genomma Lab Internacional S.A.B. de C.V stock overvalued or undervalued in 2026?
As of Oct 2, 2026, LABB trades below its calculated fair value: price 13.78 MXN, fair value 33.27 MXN, a gap of about +141% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LABB?
No. The price is what the market pays today (13.78 MXN); the fair value is what the company's own numbers justify (33.27 MXN). For Genomma Lab Internacional S.A.B. de C.V the two are 19.49 MXN per share apart. That gap is exactly why we show both numbers side by side.
How much is Genomma Lab Internacional S.A.B. de C.V worth?
The market values Genomma Lab Internacional S.A.B. de C.V at about 13.5B MXN (market capitalisation, as of Oct 2, 2026). Per share that is 13.78 MXN; our models calculate a fair value of 33.27 MXN per share.
What do the bullish and bearish scenarios say about LABB?
Our models span a range for Genomma Lab Internacional S.A.B. de C.V: cautious scenario 22.56 MXN, base 33.27 MXN, optimistic 45.39 MXN per share (as of Oct 2, 2026, price 13.78 MXN). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of LABB?
Genomma Lab Internacional S.A.B. de C.V trades at a price-to-earnings ratio of 8.3 (as of Oct 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 33.27 MXN is built from several models across several years. Other multiples: PEG 0.9, P/B 1.2, P/S 0.8, EV/EBITDA 3.9.
What is the PEG ratio of LABB?
The PEG ratio of Genomma Lab Internacional S.A.B. de C.V is 0.86 (P/E divided by earnings growth, as of Oct 2, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Genomma Lab Internacional S.A.B. de C.V (LABB)?
Balance-sheet figures for Genomma Lab Internacional S.A.B. de C.V (as of Oct 2, 2026): return on equity 14.2%, debt of 0.43 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is LABB from its 52-week high?
Genomma Lab Internacional S.A.B. de C.V trades at 13.78 MXN, about 28% below its 52-week high of 19.02 MXN and 12% above the low of 12.29 MXN (as of Oct 14, 2026). Distance from the high says nothing about value: that is what the fair value of 33.27 MXN is for.
Which stocks are comparable to Genomma Lab Internacional S.A.B. de C.V?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Genomma Lab Internacional S.A.B. de C.V stock attractive at the current price?
The data as of Oct 2, 2026: price 13.78 MXN, calculated fair value 33.27 MXN (+141%), Quality Score 59/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LABB calculated?
We run Genomma Lab Internacional S.A.B. de C.V through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 33.27 MXN, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Genomma Lab Internacional S.A.B. de C.V currently trades 59 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Genomma Lab Internacional S.A.B. de C.V (LABB)?
The closing price on Oct 14, 2026 was 13.78 MXN. Our model-based fair value is 33.27 MXN, about +141% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Genomma Lab Internacional S.A.B. de C.V right now?
The price is below even our cautious bear case (22.56 MXN). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (59/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (22.56 MXN to 45.39 MXN) leaves room in how you read the outcome.
Key figures of Genomma Lab Internacional S.A.B. de C.V
How large is the market capitalisation of Genomma Lab Internacional S.A.B. de C.V (LABB)?
The market capitalisation of Genomma Lab Internacional S.A.B. de C.V is 13.5B MXN (≈ $729M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Genomma Lab Internacional S.A.B. de C.V (LABB)?
The price-to-sales ratio of Genomma Lab Internacional S.A.B. de C.V is 0.76 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Genomma Lab Internacional S.A.B. de C.V (LABB)?
Earnings per share at Genomma Lab Internacional S.A.B. de C.V are 1.66 MXN (price ÷ EPS = P/E 8.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Genomma Lab Internacional S.A.B. de C.V (LABB)?
The dividend yield of Genomma Lab Internacional S.A.B. de C.V is 5.8% (payout 48.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Genomma Lab Internacional S.A.B. de C.V (LABB)?
The net margin of Genomma Lab Internacional S.A.B. de C.V is 9.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Genomma Lab Internacional S.A.B. de C.V (LABB)?
The return on equity (ROE) of Genomma Lab Internacional S.A.B. de C.V is 14.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Genomma Lab Internacional S.A.B. de C.V (LABB)?
On an EBIT basis the return on assets of Genomma Lab Internacional S.A.B. de C.V is 15.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Genomma Lab Internacional S.A.B. de C.V (LABB)?
The operating margin of Genomma Lab Internacional S.A.B. de C.V is 20.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Genomma Lab Internacional S.A.B. de C.V (LABB)?
Revenue at Genomma Lab Internacional S.A.B. de C.V is growing −6.0% versus a year earlier (3y avg +1.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Genomma Lab Internacional S.A.B. de C.V (LABB)?
Earnings per share at Genomma Lab Internacional S.A.B. de C.V are growing +3.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Genomma Lab Internacional S.A.B. de C.V (LABB) carry?
The net debt of Genomma Lab Internacional S.A.B. de C.V is 1.7B MXN (fiscal year 2025, ≈ 0.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Genomma Lab Internacional S.A.B. de C.V in the live analysis
One click puts Genomma Lab Internacional S.A.B. de C.V on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
Thin data
Oct 2, 2026